Thus, although soluble ST2 may counteract circulating IL‐33 activity, the high systemic levels of soluble ST2 in RA could reflect enhanced inflammation, which is supported by the observed correlation with the CRP level. The gene discussed is IL33; the disease is rheumatoid arthritis.